MDMA

By Drug Science,
Mind Medicine Australia

With Support from
Norrsken Mind

Part I - History and Law

Drug Science was formed by a committee of scientists with a passionate belief that the pursuit of knowledge should remain free of all political and commercial interest.

Founded in 2010 by Professor David Nutt, following his removal from his post as Chair of the Advisory Council on the Misuse of Drugs, Drug Science is the only completely independent, science-led drugs charity, uniquely bringing together leading drugs experts from a wide range of specialisms to carry out ground-breaking research into drug harms and effects.

The Drug Science mission is to provide an evidence base free from political or commercial influence, creating the foundation for sensible and effective drug laws. Equipping the public, media and policy makers with the knowledge and resources to enact positive change.

Drug Science want to see a world where drug control is rational and evidence-based; where drug use is better informed and drug users are understood; where drugs are used to heal not harm.

@Drug_Science **/DrugScienceISCD**

Mind Medicine Australia is a registered charity working to alleviate the suffering and suicides caused by mental illness by expanding treatment options through the safe, clinical use of psychedelic-assisted therapies to treat depression, trauma, addictions and other intractable conditions. MMA's wholly clinical focus includes building a national ecosystem encompassing professional development for health practitioners through the world-leading Certificate in Psychedelic-Assisted Therapies (CPAT)™, patient access pathways, medicine supplies, regulatory and research advancements, clinical rollouts and widespread awareness and education.

MMA made global history through their successful rescheduling applications for psilocybin and MDMA making Australia the first nation in the world to reschedule these medicines for clinical use in 2023. You can learn more about our key achievements on our website.

Norrsken Mind is a non-profit foundation dedicated to advancing psychedelic science. The foundation funds high-quality, independent research into the therapeutic potential of psychedelics for mental health disorders, along with non-profit initiatives to lay the foundation for a future integration of these treatments into healthcare.

Beyond research funding, Norrsken Mind promotes public education, stakeholder engagement, and policy dialogue. By offering grants and facilitating partnerships, Norrsken Mind aims to create the necessary conditions for psychedelic treatments to be rigorously studied, responsibly implemented, and ultimately accessible to patients in need.

Norrsken Mind actively works to mobilize philanthropic capital for psychedelic science. The foundation is funded through donations from committed benefactors and its affiliation with Norrsken Foundation.

Drug Science has received grant support from Norrsken Mind, which supported the development of this educational material.

/company/norrsken-mind

What is MDMA?

3,4-methylenedioxy methamphetamine (**MDMA**) is chemically related to the stimulant drug, amphetamine

MDMA has some stimulant effects in humans, along with distinct additional effects that class it as an **"empathogen"** or **"entactogen"**

The empathogenic effects of MDMA increase feelings of closeness with others, and promote bonding

These effects of MDMA have been shown to be beneficial in support of certain forms of psychotherapy for mental health conditions such as post-traumatic stress disorder (**PTSD**)

MIND MEDICINE AUSTRALIA

Drug Science

History of MDMA

MDMA was first synthesised in 1912 by chemists at the pharmaceutical company, Merck in Germany, and was patented at that time as an intermediate in the synthesis of a compound, hydrastinine, that had been developed as a regulator of bleeding. MDMA at that time was called "methylsafrylamin" in Merck internal documentation.

1912

Basic pharmacological tests were halted for economic reasons.

1927

Toxicological studies were conducted on animals as part of the CIA'S MK-ULTRA program. but MDMA was not tested in humans - by Merck- until 1959.

1953-53

The first published protocol for MDMA synthesis appeared in a Polish scientific journal.

1960

MDA, a close chemical relation to MDMA, was known and used non-clinically throughout the 60s.

1960s

The first seizure of MDMA tablets was reported in Chicago.

1970



History of MDMA

Dr **Alexander "Sasha" Shulgin** became aware of MDMA in the course of his systematic chemical and pharmacological exploration of phenethylamines as psychoactive agents. Around 1976, it is believed that he bioassayed (i.e. self-administered) MDMA in small, incrementally increasing, doses, and discovered its very particular effects on mood - but less so on cognition.

MDMA was used extensively as an adjunct to psychotherapy for the treatment of anxiety and post-traumatic stress disorder, and in couples counselling. However, very little formal research was conducted to investigate/establish its therapeutic applications.

In 1977, Shulgin introduced MDMA to his friend **Leo Zeff**, a San Francisco Bay Area psychotherapist, and Zeff delayed his retirement to introduce it in turn to hundreds, possibly thousands, of psychologists and psychotherapists across the USA.

Awareness of MDMA's prosocial and mood-enhancing effects spread through the 1980s and, probably inevitably, it became popular in the underground electronic music scene. Prior to this, the drug had been known by therapists as "Adam"; at this time, in favour of the arguably more appropriate name "Empathy", MDMA became known in street drug culture as "Ecstasy."

MIND MEDICINE AUSTRALIA

Drug Science

MDMA Use in the USA

1977

MDMA was used therapeutically across the USA from 1977, following its introduction by Alexander Shulgin to psychiatrist, Leo Zeff, and subsequent widespread promotion by Zeff as an adjunct to psychotherapy

1979

By 1979, a small non-clinical market had developed for the drug "Ecstasy", a street name chosen over the more appropriate "Empathy"

1980s

The "Boston Group" started mass manufacture and distribution for therapeutic applications

1983

The competing, "Texas Group", took up manufacture, promoting MDMA aggressively to the recreational dance/club market as "Ecstasy"

1985

US state police departments and other authorities, particularly the Drug Enforcement Administration (DEA), responded swiftly to the proliferation of non-clinical MDMA use, and it was placed in Schedule 1, the most restrictive schedule, by emergency ruling in 1985

1988

Its classification as having no medical use, high abuse potential and lacking accepted safety for use under medical supervision, was cemented by the DEA in 1988, after an extensive process of professional and public consultation; in so doing, the DEA overruled the advice of its own court appointee, Administrative Law Judge Francis L. Young

MDMA Use in the UK and Europe

MDMA reached the UK relatively early, sometime in the 1970s, and **was made illegal in 1977** following the discovery of a clandestine laboratory in the Midlands.

MDMA was scheduled in the Netherlands in 1988. Other European countries closely followed suit.


EVIL OF ECSTASY

Danger drug that is sweeping disco and ruining lives

PILL POTTY 1 PILL POTTY 2 PILL POTTY 3

HORROR OF MY DREAMS

TOUGH WAS TOO SUCH!

It saps all my energy

UK

The UK government introduced an amendment to the 1971 Misuse of Drugs Act, making MDMA and its analogues Class A drugs.

Broader awareness of MDMA reached the UK from New York in the **early 1980s**, and **quickly became popular** along with the emergence of house and techno electronic dance music from Chicago and Detroit.

While the UK had gone through its own processes of scheduling in 1977, **enforcement began in earnest in 1985**.

MDMA Use in Australia

In Australia, for people aged 14 and older:

- Around **12-14%** have used MDMA/ecstasy at least once in life (1,2)
- Approximately **2-3% of Australians** reported MDMA use in the past 12 months (1,2)
- Australia has **one of the highest rates of MDMA use globally**, with availability increasing since 2023 (3)

(1) NDARC, *Ecstasy/MDMA use and markets in Australia*, 2013–2022
(2) NDSHS, *National Drug Strategy Household Survey* 2022-2023
(3) EUDA, *EU Drug Market: MDMA — Global context*

Australia – World First

Until mid-2023, MDMA was classified as a Schedule 9 (prohibited and illegal) substance in the Australian Poisons Standard.

From 1 July 2023, the Therapeutic Goods Administration (TGA) amended the Poisons Standard to **allow MDMA to be prescribed** as a Schedule 8 controlled medicine **specifically for the treatment of post-traumatic stress disorder (PTSD)** by authorised psychiatrists under strict controls.

For all other uses (including recreational), MDMA remains a Schedule 9 substance.

There is still no widely registered MDMA medicine on the Australian Register of Therapeutic Goods (ARTG). When prescribed, MDMA is sourced under special authorisation for therapy.

Scheduling of MDMA

US authorities, particularly the Drug Enforcement Administration (DEA), responded swiftly to the proliferation of non-clinical MDMA use, and it was placed in Schedule 1, the most restrictive schedule, by emergency ruling in 1985.

Schedule I	Most potential for abuse and dependence
Schedule II	High potential for abuse and dependence
Schedule III	Moderate potential for abuse and dependence
Schedule IV	Low potential for abuse and dependence
Schedule V	Lowest potential for abuse and dependence

Response by the therapeutic community was rapid and vocal, and the DEA convened a process of professional and public hearings to enable assessment of the medical value of MDMA.

The classification of MDMA as having no medical use, high abuse potential and lacking accepted safety for use under medical supervision, was cemented by the DEA in 1988, after an extensive process of professional and public consultation; in so doing, the DEA overruled the advice of its own court appointee, Administrative Law Judge Francis L. Young.

MDMA manufacture and use consequently went underground, but continued to expand in similar manner to other recreational drugs in high demand.

Why was MDMA banned?

MDMA is classified as a stimulant of the amphetamine class, and also as a hallucinogen. Hence, on both counts, MDMA is regarded by government authorities as a drug of abuse.

US President Nixon's **"War on Drugs"** evolved into President Reagan's **"Just Say No"** campaign.

The US government and medical/research community promulgated concerns, largely unsupported by clinical evidence, about neuronal damage and other long-term health impacts.

DEA spokesperson: *"All of the evidence the DEA has received shows that MDMA abuse has become a nationwide problem and that it poses a serious health threat."*

Effective opposition to the official line was hampered by the lack of evidence of therapeutic applications - formal research not conducted partly through fears among psychotherapists that community awareness of MDMA would lead to widespread non-clinical use, with consequent risk of 60s-like response from authorities.

Ironically, widespread non-clinical use did indeed occur, resulting in a small but significant number of deaths and other adverse health outcomes. This **"recreational"** use in unsupervised settings provided evidence and impetus for ever-increasing global law enforcement efforts to eliminate MDMA use in the community

Click here to watch Nancy Reagan warning Americans as part of the "Just Say No" Campaign

MIND MEDICINE AUSTRALIA

Drug Science

Social Impact of the War on Drugs

Effects on developing economies through economic exploitation & supply reduction efforts

Diversion of resources to law enforcement and prison-industrial complex

Increases in associated crime, social dislocation, mental illness & comorbidity

Increased incarceration rates, particularly in USA, UK, Europe and Australia

Establishment & sustenance of global illicit drug trade, cartels & paramilitary organisations

MIND MEDICINE AUSTRALIA

Drug Science

Scientific & Healthcare Impact of the War on Drugs

1. Stigma associated with MDMA and psychedelic research
2. Bureaucracy associated with research approval
3. Limitations on fundamental neurobiology research
4. Funding restrictions on biomedical research
5. Limited/no funding for medical treatments

The Intervening Years

No research was conducted into the potential therapeutic applications of MDMA between 1985-2000.

However, both the US National Institute of Health and the US National Institute of Drug Abuse conducted some animal- based research to intentionally demonstrate the harms and risks of MDMA.

Nonetheless, since MDMA was placed in Schedule 1 in 1985, over 5000 academic articles on MDMA have been published, and **over 1100 human volunteers have been administered MDMA**, including human research into driving impairment conducted at Swinburne University, Australia.

The MDMA Renaissance

1986	The Multidisciplinary Association for Psychedelic Studies (MAPS) was founded by Rick Doblin to develop MDMA and other psychedelics as medicines.
1986 1990	MAPS began funding **animal toxicity studies & human safety studies** at Stanford University and John Hopkins University.
1996	Charles Grob publishes the first FDA-approved, double-blind, placebo-controlled **Phase I** dose-response safety study of MDMA in healthy volunteers.
2004	The first MAPS-sponsored **Phase 2** clinical trial of MDMA-assisted psychotherapy for PTSD is approved by the FDA, marking the transition from safety work to formal efficacy studies.
2004 2017	Six **Phase 2** trials of MDMA-assisted therapy for PTSD are completed across North America, Europe and Israel, alongside smaller studies in anxiety related to life-threatening illness and social anxiety in autistic adults. • Early pooled and long-term follow-up analyses suggested that a majority of treated PTSD participants no longer met diagnostic criteria with a generally manageable safety profile. • These analyses have since been retracted and their estimates are now treated with caution while newer data and methods are used to reassess long-term outcomes.

The MDMA Renaissance

2017	The US FDA grants **Breakthrough Therapy designation to MDMA-assisted psychotherapy for PTSD**, recognising its potential to offer substantial improvement over existing treatments and supporting an expedited path through the drug-development and review process.
2017 2023	Two multi-site **Phase 3** RCTs (MAPP1 & MAPP2) in ~200 adults with moderate-to-severe PTSD found that adding 2–3 day-long MDMA sessions (80–120 mg with an optional supplemental dose) to a 12-week course of manualised psychotherapy produced roughly double the reduction in CAPS-5 PTSD scores compared with placebo plus therapy. In these trials, about half to two-thirds of participants no longer met PTSD criteria at follow-up, and adverse events were generally manageable in carefully screened patients.
2020 2023	The FDA grants an **Expanded Access programme** for MDMA-assisted therapy for PTSD, allowing up to ~50 patients at around 10 US sites to receive MDMA outside the phase 3 trials.
2023 2024	Lykos Therapeutics (the public-benefit company spun out of the MAPS clinical programme) submits a New Drug Application to the FDA for MDMA-assisted therapy in PTSD, based mainly on MAPP1 and MAPP2. In June 2024 an advisory committee votes against approval, and in August 2024 the FDA issues a Complete Response Letter requesting additional phase 3 evidence before MDMA can enter routine clinical use.

Hear a U.S. Army veteran speak on how MDMA helped treat PTSD

Beyond PTSD: Emerging Therapeutic Targets

Early-phase studies suggest that MDMA-assisted psychotherapy may have applications beyond PTSD, but all of these uses remain experimental and unapproved.

Alcohol Use Disorder (AUD)	Open-label feasibility work from Bristol has tested MDMA-assisted psychotherapy after detox in people with alcohol use disorder, finding good tolerability and encouraging reductions in harmful drinking patterns, with further controlled trials in development (Sessa et al., 2021).
Social Anxiety in Autistic Adults	A small randomised, placebo-controlled pilot trial in autistic adults with marked social anxiety reported substantial and sustained reductions in social fear and avoidance after two MDMA-assisted psychotherapy sessions, supporting further research in this population (Danforth et al., 2018).
Eating Disorders	Early theory papers and exploratory analyses (Brewerton et al., 2020) suggest MDMA-assisted therapy might help when eating disorders co-occur with PTSD, with secondary data from a phase-3 PTSD trial showing reductions in eating-disorder symptoms (EAT-26 scores) after MDMA-AT versus placebo (Brewerton et al., 2022).
Couples and Relational Distress	MDMA has been combined with cognitive-behavioural conjoint therapy for PTSD in pilot work with couples, with preliminary evidence of improvements in PTSD symptoms, relationship functioning and post-traumatic growth (Monson et al., 2020).

Listen to Drug Science Podcast featuring Michael & Annie Mithoefer on MDMA and couple counselling

Physical Safety of MDMA

Clinical trials & MDMA-Assisted Psychotherapy	Naturalistic / unregulated settings
Typical physical effects during the experience: transient increases in heart rate and blood pressure, jaw clenching, sweating, nausea, reduced appetite and insomnia. Short-lived after-effects may include fatigue, poor sleep and low appetite.	
• In controlled trials, MDMA is given at fixed doses with medical screening, ECGs and continuous monitoring. • Serious medical events have been uncommon: pooled phase- 2 and phase-3 data report no MDMA-attributable deaths, no signal for organ toxicity, and no evidence of dependence or withdrawal within trial protocols. • Clinical programmes limit total dose and number of sessions, avoid polydrug use and provide clear guidance on hydration, rest and post-session care to minimise physical risk.	• Recreational use often involves uncertain pill purity, higher or repeated doses, mixing with other substances or medications, hot and crowded venues, physical exertion and sleep loss. • A small minority develop serious complications such as **hyperthermia** (dangerously high body temperature from overheating and exertion), **hyponatraemia** (dangerously low blood sodium, more likely in young women; caused by MDMA-stimulated release of antidiuretic hormone, which promotes water retention, compounded by excessive water intake), **arrhythmias** (abnormal heart rhythms), **serotonin syndrome** (toxic serotonin overstimulation, often from polydrug use and/or interactions with other serotonergic medications) or **multi-organ failure** (collapse of several vital organs in severe toxicity). • Concerns about long-term neurotoxicity and subtle cognitive change arise mainly from heavy, chronic “ecstasy” use; dose, frequency, environment and adulterants appear to be major contributors to these risks.

Potential Psychological Risks of MDMA

Clinical trials & MDMA-Assisted Psychotherapy	Naturalistic / unregulated settings
• MDMA reliably alters mood, perception and social connectedness. • In MDMA-assisted psychotherapy, many participants report increased empathy, openness and emotional processing, alongside episodes of intense anxiety, fear or grief as traumatic material surfaces. • Most psychological effects resolve within days with preparation, skilled support and integration sessions. • A minority experience **worsening PTSD symptoms**, low mood, suicidal ideation or transient dissociation during or after dosing. • To reduce these risks, trials typically exclude psychotic/bipolar disorders and use close monitoring and structured follow-up.	• Recreational users often report acute euphoria, sociability and emotional closeness, followed by a short-term "comedown" over the next days. • **Common after-effects** include fatigue, irritability, sleep disturbance and low mood, likely related to monoamine depletion, sleep loss and context. • **Heavy or frequent ecstasy use** is associated with higher rates of anxiety and depressive symptoms and small but measurable impairments in memory and other cognitive functions (often confounded by polydrug use). • MDMA has some abuse and dependence potential: repeated high-dose use can lead to tolerance, cravings and withdrawal-like symptoms (fatigue, low mood, poor concentration). Careful screening, preparation and integration are needed to reduce these risks.

Psychedelic Ethics

Check MAPS MDMA-Assisted Psychotherapy Code of Ethics

MDMA-assisted therapy uses explicit ethical codes to protect people in very vulnerable states. Key principles include:

Safety & Screening	• Careful medical and psychological screening to confirm MDMA therapy is appropriate and that people have adequate support and a safe living situation. • Clear crisis plans, backup cover and emergency contacts; rapid response to any medical or psychological emergency. • Ongoing integration and no “abandonment” – planned endings and referrals when needed.
Confidentiality & Transparency	• Strong protection of privacy and secure storage of notes/recordings within legal limits (e.g. risk of harm, abuse, court orders). • Informed consent as an ongoing process: clear explanation of the medicine, risks, benefits, alternatives, use of touch, recording, fees and who else may be present.
Boundaries, Touch & Sexual Ethics	• Awareness of power differences and heightened suggestibility in altered states. • Clear rules on touch: only for safety or agreed therapeutic purposes, never sexual, and always stoppable by the participant. • Absolute ban on sexual contact during or after treatment, plus safeguards against exploitation and problematic dual relationships.
Diversity & Therapist Responsibility	• Commitment to non-discrimination, cultural humility and inclusive practice. • Extra care with consent and influence in non-ordinary states. • Ongoing supervision, self-reflection and support so therapists remain safe, grounded and ethical.

MDMA-Assisted Psychotherapy Model

Listen to Drug Science Podcast featuring Dr Ben Sessa and Chris Trudgian on MDMA-Assisted Therapy

Modern MDMA trials use a structured, manual-based psychotherapy model rather than a “drug-only” approach. A typical 3-stage protocol:

1. Preparation (Usually 3+ non-drug sessions)

Careful screening for medical, psychiatric and medication risks; confirm PTSD diagnosis and exclusions.

Building trust and safety with two therapists (often mixed-gender); exploring trauma history, coping patterns and support network.

Explaining MDMA's effects, session structure and possible difficult experiences; agreeing ground rules around touch, breaks and recording.

Consent, boundaries (including any use of touch), recording and session logistics are discussed and agreed in advance.

Practising basic grounding and emotion-regulation strategies the patient can use during MDMA sessions.

2. MDMA Dosing Sessions (2-3 all-day sessions)

Conducted in a quiet, homelike room with two trained therapists present throughout.

Standardised MDMA dosing with continuous monitoring of vitals and mental state; rescue medication available if needed.

Therapists adopt an “inner-directed" stance: supporting the patient to follow emerging emotions and memories, with flexible use of exposure, cognitive, somatic and relational techniques rather than a rigid script.

3. Integration (multiple follow-up sessions)

Processing the MDMA sessions in detail; linking insights to life events, relationships and personal values.

Supporting behaviour change (e.g. avoiding triggers, rebuilding routines, reconnecting socially) and coordinating with ongoing care to maintain gains and monitor safety.

MDMA Harm Reduction for Recreational Use

MDMA use always carries risk, but **certain practices can substantially reduce the chance of serious harm in recreational contexts:**

- Check for unexpected, unknown or potentially dangerous substances (e.g. PMA/PMMA, cathinones) using reagent test kits. In the UK, you can also use drug-checking (pill/powder testing) services provided by **The Loop**.
- Avoid redosing repeatedly; start with a single, moderate dose and wait before considering more.
- Leave substantial time between MDMA sessions (months, not days or weeks) to reduce tolerance and possible neurotoxicity.
- Sip water regularly but avoid over-drinking (e.g. ~500 ml per hour in hot, active settings, less if resting).
- Take breaks from dancing, cool down, and watch for overheating or confusion; seek help early.
- Choose venues with good ventilation, chill-out areas, free water and trained staff/first-aid.
- Stay with trusted friends and have a plan for getting home safely.
- Pay attention to official alerts and local harm-reduction services that flag high-dose or dangerous pills in circulation, and adjust behaviour accordingly.

Additional Resources

The Loop

Drugs and Me

MDMA/Ecstasy Harm Reduction Infographics (The Loop)

Ecstasy pills #SizeMatters Infographics (The Loop)

MDMA Dose and Onset (Drugs and Me)

Guide to Drug Combinations (TripSit)

Current Legal Status of MDMA

National Schedules

- US Schedule 1
- UK Schedule 1
- Australia Schedule 9 (with a Schedule 8 therapeutic pathway for PTSD and associated comorbidities)

UN Convention on Psychotropic Substances (1971)

- MDMA is explicitly listed in Schedule 1

These schedules characterise **MDMA as a high-risk substance with high abuse potential and no recognised medical use** (US Schedule I, UK Schedule 1, Australia Schedule 9), although Australia has introduced a Schedule 8 pathway for MDMA-assisted therapy in PTSD treatment.

Research is permitted with appropriate ethics approval and the necessary state and national controlled-drug licences.

Evolving Regulatory Guidance on MDMA

Regulators are increasingly focused not on whether MDMA may be studied, but on how MDMA-assisted therapies should be evaluated and, if effective, integrated into clinical care.

United States — FDA draft guidance

The US Food and Drug Administration (FDA) has issued draft guidance for industry, *Psychedelic Drugs: Considerations for Clinical Investigations*, which sets out expectations for trials of psychedelic drugs, explicitly including MDMA. It covers study design, dosing-session procedures, integration of psychotherapy, management of acute psychological effects and suicidality, cardiac and temperature monitoring, and assessment of abuse potential. MDMA is also referenced in the 2023 VA/DoD *Clinical Practice Guideline for PTSD and Acute Stress Disorder*.

Europe — EMA depression guideline

The European Medicines Agency (EMA) has updated its *Guideline on the clinical investigation of medicinal products for the treatment of depression* (Revision 3), including a dedicated section on psychedelic treatments that explicitly mentions MDMA and sets expectations for study design, timing of primary endpoints in single-course treatments, durability of effect, and long-term safety follow-up.

Commentary in leading journals (including *JAMA* and the *New England Journal of Medicine*) and stakeholder feedback to the EMA describe these FDA and EMA texts as early regulatory frameworks for psychedelic medicine, stressing the need to adapt trial design and endpoints to single-course psychedelic treatments, standardise the psychotherapy component, manage blinding to conspicuous drug effects, and generate robust data on durability and long-term safety.

National Medical Pathways

Switzerland — Limited Medical Use via Exceptional Authorisations

Since 2014, Switzerland's Federal Office of Public Health has granted exceptional single-patient licences allowing medical use of MDMA (alongside psilocybin and LSD) for severe, treatment- resistant conditions in a small number of specialist or university clinics, under strict case-by-case review.

Israel — Government-Supported Compassionate Use

Since 2019, Israel's Ministry of Health has run a compassionate-use programme allowing MDMA-assisted psychotherapy for about 50 adults with severe, treatment-resistant PTSD at several hospitals, representing the first national government-backed access scheme for therapeutic MDMA.

Canada — Special Access Program (SAP)

Regulatory amendments in 2022 restored Health Canada's ability to authorise “restricted drugs", including MDMA, via the Special Access Program when standard treatments have failed or are unsuitable. 2023 guidance explains how clinicians can request MDMA-assisted psychotherapy on a case-by-case basis for serious or life-threatening conditions.

Netherlands — State Commission Recommending Regulated Access

In 2023-2024, the Dutch government's State Commission on MDMA issued the report MDMA

Australia — First National Down-Scheduling for Clinical Use

First National Down-Scheduling for Clinical Use: In 2023, the Therapeutic Goods Administration reclassified MDMA so that, from 1 July 2023, specified preparations may be prescribed as Schedule 8 medicines for PTSD by authorised psychiatrists, while remaining Schedule 9 otherwise – making Australia the first country to nationally permit MDMA-assisted therapy in routine clinical practice.

What does this mean for doctors?

What is preventing doctors from considering MDMA-assisted therapies?

- Many clinicians see the evidence for MDMA-assisted psychotherapy (especially for PTSD) as promising but still evolving, particularly around long-term outcomes, comparative effectiveness and safety in routine practice.
- Regulatory status is complex: MDMA remains a tightly controlled substance in most jurisdictions, with access largely confined to clinical trials, special access / compassionate-use schemes, or a few highly regulated national pathways.
- Public health systems in most jurisdictions lack clear service models and training providers, with uncertainty around scope of practice and indemnity, though Australia represents a significant exception, complete with an authorised prescriber framework that defines clinical roles and oversight, supported by growing accredited training infrastructure, together constituting an operational model other countries can learn from
- Stigma, mixed media coverage and concern about hype or commercial and ideological interests make some clinicians cautious.

Why is the evidence base still viewed as incomplete?

- Historical prohibition and scheduling have slowed research and limited large, publicly funded or government-sponsored trials.
- Many existing studies use relatively small, highly selected samples, have short or moderate follow-up, and face methodological challenges (e.g. blinding, expectancy effects, choice of control condition).
- Completed Phase 3 trials demonstrated statistically significant and durable outcomes, providing a stronger evidence base than earlier-phase studies, though questions remain about replication and generalisability
- Real-world data and health-economic evidence remain scarce globally, but Australia's authorised prescriber pathway is now generating precisely this kind of evidence, with much data being reported to ANU's psychedelic-assisted psychotherapy registry
- Questions remain about optimal dosing and session structure, which patient groups benefit most, therapist training and team composition, and how to scale MDMA-assisted psychotherapy safely and ethically beyond specialist centres.

What does this mean for patients?

Current treatment landscape

- Many patients with PTSD and other trauma-related conditions do not achieve adequate relief from existing treatments.
- Trauma-focused psychotherapies (e.g. TF-CBT, EMDR) are often described with a “rule of thirds": ~⅓ achieve full remission, ~⅓ show partial improvement, ~⅓ have little meaningful benefit
- First-line medications (SSRIs/SNRIs) can help some patients but often leave residual symptoms and can cause side effects that limit adherence or lead to discontinuation
- Media coverage and early trial results have raised expectations around MDMA-assisted therapy as a potential “breakthrough" for PTSD, even though access and long-term evidence remain limited.

Access to MDMA-assisted therapy

- In most countries, MDMA remains a controlled substance; access is largely confined to clinical trials, special access/ compassionate-use programmes, or in a few specialised centres.
- Australia is a notable exception: authorised clinics are now operational across major cities and a growing number of regional areas, providing patients with genuine access under a regulated framework
- Even when patients are interested and clinicians are sympathetic, MDMA-assisted psychotherapy is often unavailable locally, or offered only in a small number of specialist centres, sometimes with long waiting lists.

Where patients turn instead

- Some patients seek help in unregulated or underground settings (retreats, informal guides, online or black-market supply), where standards of screening, support and integration are highly variable.
- This can expose vulnerable people to clinical, psychological, financial and ethical risks, and may widen inequities if only those with resources can travel or pay out of pocket.

The Role of the Medical Student

Medical students need a clear, balanced understanding of MDMA-assisted therapy, particularly for PTSD and other trauma-related conditions—its evidence base, regulatory status, and ethical issues—along with a solid grasp of potential benefits and risks, so they can correct misinformation and help patients weigh options within a broader treatment plan.

They can also support progress by contributing to well-designed research, critical appraisal, and rigorous reporting of both benefits and harms, while advocating for safe settings, robust consent, and appropriate safeguards.

Over time, they can serve as informed communicators to colleagues, patients, and policymakers, and help shape future training standards, services, and policy if these therapies enter mainstream care.

For Australian medical students, in particular, this is an area of immediate clinical relevance: the field is moving rapidly, with regulated access already available and the evidence base actively evolving.

Where can you find out more?

Drug Science

Drug Science Podcast

Mind Medicine Australia

David Nutt's Book, Drugs Without the Hot Air: Making Sense of Legal and Illegal Drugs (2012)

David Nutt's Book, Psychedelics: The revolutionary drugs that could change your life - a guide from the expert (2024)



References

Brewerton TD, et al. (2022). MDMA-assisted therapy significantly reduces eating disorder symptoms in a randomized placebo-controlled trial of adults with severe PTSD. *Journal of Psychiatric Research*. 149:128–135.

Colcott J, et al. (2024). Side-effects of MDMA-assisted psychotherapy: a systematic review and meta-analysis. *Neuropsychopharmacology*. 49(8):1208–1226.

Danforth AL, et al. (2018). Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study. *Psychopharmacology*. 235(11):3137–3148.

Drug Policy Alliance. (2020). A Brief History of the Drug War. *Drug Policy Alliance*. [Accessed 07.01.2026].

Mitchell JM, et al. (2023). MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. *Nature Medicine*. 29(10):2473–2480.

Monson CM, et al. (2020). MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial. *European Journal of Psychotraumatology*. 11(1):1840123.

Sessa B, et al. (2021). First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder. *Journal of Psychopharmacology*. 35(4):375–383.

Smith KW, et al. (2022). MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: a systematic review with meta-analysis. *Journal of Clinical Pharmacology*. 62(4):463–471.

Ung H, et al. (2025). Long-term neurocognitive side effects of MDMA in recreational ecstasy users following sustained abstinence: a systematic review and meta-analysis. *Journal of Psychopharmacology*. 2025 Nov 19:2698811251389559.

drugscience.org.uk